Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16575072 | 1.00 | CCNE1 (0.36) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL7875278 | 1.00 | CCNE1 (0.36) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL8129220 | 1.00 | CCNE1 (0.36) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL2624001 | 1.00 | CCNE1 (0.36) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL2353518 | 0.91 | CCNE1 (0.36) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL11942083 | 0.89 | CCNE1 (0.32) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL12757780 | 0.88 | CCNE1 (0.33) | CCNE1CDK2GSK3BNPC1RAB9A | |
| SCHEMBL14731660 | 0.84 | CCNE1 (0.36) | CCNE1CDK2GSK3B | |
| SCHEMBL12048372 | 0.84 | CCNE1 (0.36) | CCNE1CDK2GSK3B | |
| SCHEMBL14864657 | 0.84 | CCNE1 (0.36) | CCNE1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| EP-2162431-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9452154-B2 | Methods for treating HCV | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9393256-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150141353-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2282762-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2162431-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CCNE1 44/4885CDK2 29/4885GSK3B 1615/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | CCNE1 605/4885CDK2 274/4885GSK3B 1683/4885 |
| US-20160354425-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CCNE1 4341/4885CDK2 3592/4885GSK3B 1408/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | CCNE1 4341/4885CDK2 3592/4885GSK3B 1408/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CCNE1 864/4885CDK2 343/4885GSK3B 2041/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CCNE1 4341/4885CDK2 3592/4885GSK3B 1408/4885 |
| US-20150141353-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CCNE1 4341/4885CDK2 3592/4885GSK3B 1408/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CCNE1 4341/4885CDK2 3592/4885GSK3B 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.